Author:
Harshman Lauren C.,Srinivas Sandy,Kamaya Aya,Chung Benjamin I.
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Motzer, R. J. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16–24 (2006).
2. Rini, B. I. Tyrosine-kinase inhibitors in a presurgical setting. Presented at the American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium, 2009 February 26–28, Orlando, FL, USA.
3. Thomas, A. A. et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol. 181, 518–523 (2009).
4. Wood, C. G. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin. Cancer Res. 13, 697s–702s (2007).
5. Escudier, B. et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1280–1289 (2009).
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献